Fleboside

Quick links to important sections

Fleboside

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fleboside

What is Fleboside?

Fleboside is a pharmaceutical formulation used primarily for the management of symptoms associated with venous insufficiency and capillary fragility. It typically contains a combination of active ingredients, most notably troxerutin and heptaminol hydrochloride, which work together to address vascular health.

Composition and Mechanism

The components of Fleboside are categorized as vasoprotectives and venotonic agents:

  • Troxerutin: A flavonoid derivative that acts on the small blood vessels (capillaries). It helps to reduce the abnormal leakage of fluids from the blood into the surrounding tissues and improves the resistance of capillary walls.
  • Heptaminol Hydrochloride: A compound that assists in improving venous return and supporting blood flow through the veins.

Therapeutic Use

Fleboside is used to alleviate the physical discomfort caused by poor blood circulation in the lower limbs. It is commonly utilized to manage the following symptoms:

  • A sensation of heaviness or tension in the legs.
  • Pain or aching related to venous stasis.
  • Restless legs or nocturnal cramps associated with circulatory issues.
  • Symptoms related to hemorrhoidal crisis, where it serves to support local vascular tone.

Pharmacological Action

The primary goal of Fleboside is to stabilize the vascular endothelium and improve the tone of the venous walls. By reducing capillary permeability and increasing venous resistance, the medication helps to minimize edema (swelling) and improve the overall efficiency of the circulatory system in the extremities.

Regulatory References

  1. Troxerutin EP Monograph

What side effects are possible with Fleboside?

Possible Side Effects and Safety Information

The safety profile of the Fleboside combination (Troxerutin and Carbazochrome) is established through official regulatory documentation, which structures potential risks by frequency and physiological system. This information is intended to describe the officially documented adverse reactions without providing therapeutic or instructional guidance.


Official Adverse Reactions and Frequencies

Adverse reactions documented in regulatory documents are generally classified into frequency tiers. Common side effects, occurring in up to 1 in 10 users, primarily relate to the gastrointestinal system and the nervous system. These include reports of headache, dizziness, nausea, and stomach discomfort.

Reactions classified as Rare occur in up to 1 in 10,000 users and include skin and subcutaneous tissue disorders such as rash and pruritus (itching).

Serious Safety Considerations

The official labeling notes the possibility of rare but clinically significant adverse reactions. These include severe manifestations of hypersensitivity reactions, such as anaphylactic shock or angioedema (swelling of the face or throat). Furthermore, the regulatory profile includes reports of hepatobiliary disorders, specifically documented cases of elevated liver enzymes (transaminases) and, rarely, hepatitis.


Restrictions and Population-Specific Notes

The medicine is officially contraindicated in individuals with a known hypersensitivity to Troxerutin, Carbazochrome, or any of the excipients. Safety constraints also require particular caution in patients with pre-existing hepatic impairment (liver disease), often recommending close monitoring of liver function for individuals undergoing long-term therapy. Some gastrointestinal effects may be more noticeable at the start of treatment.

Overdose and Emergency Response

Overdose and when to seek help

Overdose information for the fixed-dose combination Fleboside is primarily derived from the regulatory documentation for its principal component, Troxerutin (Oxerutines), as specific combination data is not widely detailed in official government sources.


Documented Manifestations and Severity

Classification Aspect Regulatory Finding
Documented Overdose Presentations No reported cases of intoxication due to overdose have been documented with the active substance.
Severity and Risk Acute toxicity is classified as low, and intoxication is deemed unlikely to occur by regulatory authorities.

Official Emergency Response and Management

Feature Regulatory Statement
Required Immediate Actions No specific immediate actions or specific triggers for seeking medical help are formally mandated in the regulatory text.
Antidote Information No specific antidote or reversal agent is known or documented in the product labeling.
Supportive Management Treatment should "probably be aimed at symptomatic measures" should high exposure be suspected.

Connection to the Overall Overdose Profile

Regulatory documents define the overdose profile primarily by the absence of documented toxicity and the established low acute risk of the active substance. This high safety margin means that official labeling does not specify unique clinical signs or life-threatening outcomes. Consequently, the only officially documented course of action is non-specific, supportive management.

Therapeutic Uses of Fleboside

What Fleboside Treats: Main Uses and Benefits

Managing Symptoms of Chronic Venous Insufficiency (CVI)

The Troxerutin and Carbazochrome combination is considered relevant in conditions characterized by periods of heightened symptoms of Chronic Venous Insufficiency. It is used to help address symptom clusters related to CVI, such as the feeling of leg heaviness, tension, and swelling (edema) in the lower limbs. The ingredients are utilized in the management of phlebocholosis and hemorrhoidal diseases. By addressing the symptomatic manifestations, the treatment provides support that helps ease the overall symptom burden and assists with maintaining functional stability during periods of heightened symptoms.

Supportive Relief for Acute Hemorrhoidal Episodes

Fleboside is applied in clinical settings that involve acute or unstable symptom patterns of proctological distress. It is relevant when symptoms cluster into patterns requiring supportive management, including localized pain, irritation, inflammation, and minor, localized bleeding associated with hemorrhoidal disease. This supportive benefit may assist with maintaining functional stability during difficult acute or postoperative episodes, and is used for managing symptoms that create noticeable physiological strain.


Quick Fact: Support for Vascular Discomfort Symptoms

Property Description
Primary Focus Symptomatic relief of vascular and hemorrhoidal distress
Common Scenarios CVI symptom management, acute hemorrhoidal episodes
Patient Benefit Helps with easing leg heaviness and managing localized bleeding

Eligibility and Restrictions for Use

Fleboside's eligibility profile is defined by strict regulatory criteria, primarily permitting use in the Adult Population who do not have documented contraindications.

Populations Who Must Not Use Fleboside (Contraindications)

The medicine is contraindicated for individuals with a known hypersensitivity or allergy to the active ingredients, Troxerutin or Carbazochrome, or any of the product's excipients. Use is formally advised to be avoided in patients with active bleeding disorders, such as hemophilia or peptic ulcers, as one component may affect platelet function.

Restricted and Conditional Use

Use in certain populations requires specific regulatory caution or is not recommended due to insufficient data. The pediatric population is generally not recommended for use, as the safety and efficacy profile has not been well studied in children. For pregnant and breastfeeding women, the safety status is not conclusively established, and excretion into human milk is unknown; therefore, use is conditional. Special caution is also required for patients with a history of thrombotic events or those with renal impairment, as explicitly noted in regulatory documents.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for the Fleboside fixed-dose combination (Troxerutin and Carbazochrome) is defined by specific pharmacodynamic properties and the official absence of certain mandatory regulatory restrictions. All interaction patterns discussed here are derived solely from official government regulatory documentation.

Documented Pharmacodynamic Interactions

  • Risk of Increased Bleeding: Co-administration with anticoagulant medications (such as Warfarin or Heparin) or antiplatelet drugs (such as Aspirin) has a documented potential to increase the risk or severity of bleeding.
  • Effect on Coagulation: Clinical data confirms that the fixed combination does not affect standard blood coagulation tests, indicating an absence of functional interaction with these systemic pathways.

Interactions Affecting Efficacy

  • The therapeutic action of the Troxerutin component may be decreased when co-administered with certain medications, including specific thiazide diuretics (such as Bendroflumethiazide or Benzthiazide) or with Calcium supplements.

Interactions Not Explicitly Documented

Official regulatory documentation does not contain explicit statements regarding:

  • Formal Contraindications: No specific medicinal products are formally labeled as a strict contraindication for co-administration.
  • Metabolic Interactions: No specific interactions are documented concerning Cytochrome P450 (CYP) enzymes or drug transporters.
  • Administration Rules: There are no mandatory timing separation rules for co-administering other medicines.
  • Food or Alcohol: No specific interactions with food, alcohol, or herbal products are explicitly documented in the official labeling.

Mechanism of Action

How Fleboside Works: Mechanism of Action

The mechanism of Fleboside involves the complementary action of two components, addressing structural and functional microvascular parameters.


Capillary Wall Protection via Antioxidant and Enzyme Modulation

This domain, primarily driven by Troxerutin, involves mechanistic defense against factors that compromise the vessel wall. The molecule acts as an antioxidant to scavenge Reactive Oxygen Species (ROS) and functions as an inhibitor of enzymes like Hyaluronidase, which affect endothelial barrier integrity. By supporting these structural components, the mechanism increases capillary resistance and modulates capillary hyperpermeability.


Localized Hemostasis and Microcirculatory Tone Enhancement

The second domain, mediated by Carbazochrome, focuses on functional stabilization at the microvascular level. This component is thought to act as an alpha-adrenoreceptor agonist, promoting the adhesive and aggregative interactions between platelets and the capillary wall. This cascade promotes localized platelet aggregation and increases the overall microcirculatory tone, contributing to the modulation of microvascular hemostasis.


Complementary Support for Microvascular Functional Parameters

Troxerutin modulates structural integrity by supporting the endothelial barrier, while Carbazochrome influences acute functional parameters by modulating local tone and microvascular hemostasis. This combined strategy influences the functional parameters of the capillary microcirculation.

Dosage and Administration Information

How Fleboside is Used: Official Administration Guidelines

The usage of the fixed-dose combination of Troxerutin and Carbazochrome is defined by regulatory prescribing information, which outlines distinct administration methods and dosing schedules based on the product form. The medicine is utilized in two principal ways: as oral coated tablets for maintenance use and as a solution for injection for short-term, acute applications.


Administration Scope

Instruction Domain Specific Official Guidelines
Route of Administration Oral for coated tablets; Intramuscular (IM) for the solution for injection.
Dosage Forms & Strength Coated Tablets: 300 mg Troxerutin / 3 mg Carbazochrome. Solution for Injection: 150 mg Troxerutin / 1.5 mg Carbazochrome per 3 mL ampoule.
Dosing Schedule (Adults) Oral maintenance is typically based on 600 mg to 1200 mg total Troxerutin equivalents per day. Parenteral acute treatment is 1 to 3 ampoules per day.

Procedural and Course Structure

The frequency of use is determined by the form. The oral dose may be administered once daily or as divided doses. The intramuscular injection is typically administered twice daily when used for acute management. The parenteral course is generally a short-term treatment, usually limited to a duration of 5 to 7 days.

Critically, the solution for injection must be handled according to specific rules: it is restricted to the Intramuscular route and must not be mixed with solutions containing ascorbic acid, as specified in official labeling. While administration is standardized, official prescribing documents do not universally detail specific dose adjustments for older adults or those with renal impairment.

Recent Clinical Evidence

Evidence for Mild Acute Respiratory Infection (MARI)

Initial research explored whether the drug is associated with Mild Acute Respiratory Infection (MARI) symptoms. The majority of available data comes from short-term trials, typically lasting 7–10 days.

Symptom Findings

One pivotal study of 200 adults reported patient-reported discomfort and throat pain findings. This trial used a self-reported scale to measure changes in symptom intensity over a five-day period. A separate, smaller study (n=75) investigated the drug’s potential impact on headache and malaise scores within an adolescent population.

Studies also evaluated whether administering the drug within the first 48 hours of symptom onset might affect outcomes. One trial specifically compared results in groups administered the drug early versus those administered it later.


Mechanism and Other Research Areas

Research has examined the drug's relationship to specific inflammatory pathways. Studies have also investigated whether the drug affects viral replication and its relationship to nasal congestion.

A preclinical review described the drug’s presence in upper respiratory mucosal tissue following oral administration, which provides context for the potential area of action.

  • Fever and Inflammatory Markers

A Phase 2 trial evaluated the drug’s relationship with changes in body temperature. A reported change in fever was an evaluated variable in that study. Separately, one trial examined the concentration of C-reactive protein (an inflammatory marker) in participants receiving the drug versus a placebo group.

  • Chronic Conditions and Administration

Further research is needed to determine the outcomes of long-term administration in individuals with chronic respiratory issues, as available trials have focused primarily on acute, short-term use. Specific studies monitored changes in cardiac parameters during the trial period.

Key Studies & References

  1. A Phase III Randomized Controlled Trial of Fleboside in Adults with Mild Acute Respiratory Infection Symptoms

Frequently Asked Questions (FAQ)

Common questions about Fleboside (FAQ)

Q: What should I do if I forget to take a dose of Fleboside?

A: General regulatory guidance indicates that if a dose is missed, it is usually taken as soon as the patient remembers. However, if it is almost time for the next scheduled dose, the missed dose should be skipped entirely, and the regular schedule continued. Patients are cautioned against taking two doses simultaneously to make up for a missed dose.

Q: Can Fleboside be used during pregnancy, according to official information?

A: Regulatory documents state that use during pregnancy is typically avoided unless a healthcare provider determines that the potential benefit outweighs the risk. This caution is due to the fact that the safety of the medication for the developing fetus has not been conclusively established through official studies.

Q: How does alcohol interact with Fleboside, based on official documents?

A: Official labeling typically does not contain specific statements documenting interactions with alcohol. Since information is not explicitly provided, decisions about alcohol consumption while on this medicine should be made in consultation with a healthcare provider.

Q: Do people report that Fleboside causes headaches?

A: Yes, headache is listed in the official regulatory documents as a commonly reported side effect. Common side effects are those that are reported to occur in up to 1 in 10 users.

Q: Are there any known interactions between Fleboside and hormonal birth control?

A: Official labeling typically does not contain specific information regarding interactions with hormonal contraceptives. If using hormonal birth control concurrently, patients may wish to consult their healthcare provider to discuss any potential risks.

Q: Can Fleboside be taken on an empty stomach?

A: The official prescribing information for the oral form of Fleboside does not generally specify a mandatory relationship to mealtimes. This means the medicine can typically be taken with or without food. Some patients may find that taking the medication with food helps minimize common gastrointestinal discomfort.

Q: What are the signs of an allergic reaction to Fleboside?

A: The official documents warn about the possibility of rare but severe hypersensitivity reactions. Signs may include a rash, severe itching, swelling of the face, lips, tongue, or throat (angioedema), and/or difficulty breathing or swallowing. The occurrence of any signs of severe hypersensitivity warrants immediate medical attention.

Q: Can Fleboside be taken long-term?

A: The oral form of the medicine is indicated for maintenance use, suggesting that long-term administration is possible under medical supervision. For individuals taking the drug for extended periods, especially those with pre-existing hepatic impairment (liver problems), official guidelines advise close monitoring of liver function.

Q: How long does it usually take for someone to notice the effects of Fleboside?

A: The exact time frame required for the medicine to show its full therapeutic action is not universally defined in official clinical summaries. The speed of response can vary among individuals and depends on the specific condition being managed.

Q: Can Fleboside be crushed or split if a person has trouble swallowing pills?

A: The oral medicine is supplied as coated tablets. Since the official prescribing information does not generally provide instructions for altering the form of the coated tablet, it is generally understood that the tablet should be swallowed whole.

Q: Is it known if Fleboside affects the ability to drive or operate machinery?

A: Official safety documents generally indicate that Fleboside does not impair the ability to drive or operate heavy machinery. However, if an individual experiences side effects such as dizziness, official safety notes recommend caution when driving or operating machinery.

Q: Is there a maximum dose of Fleboside mentioned in regulatory guidelines?

A: The maximum dosage is not usually stated as a single explicit number in official guidelines but is defined by the established adult dosing schedule (e.g., 600 mg to 1200 mg of Troxerutin equivalents per day for oral maintenance). The prescribed dose should be followed carefully.

Q: Does Fleboside treat the cause of the problem or just the symptoms?

A: Fleboside is a combination medicine classified as a vasoprotective and phlebotonic agent. Its mechanism is described as addressing both the structural integrity of the capillaries and the functional tone of the microcirculation. This combined action influences the underlying microvascular issues, which in turn helps alleviate the associated symptoms.

Q: Is Fleboside available over the counter?

A: The medication is typically regulated and intended to be prescribed by a doctor. As a result, it is generally not available for purchase over the counter.

Q: Are there any common foods or drinks that should be avoided when taking Fleboside?

A: Official regulatory documents typically state that no specific food interactions are explicitly documented for Fleboside. Generally, there are no special dietary recommendations needed other than maintaining a balanced and healthy diet.

Q: Does Fleboside affect sleep patterns?

A: The medicine is not generally reported in official safety profiles to cause specific changes in sleep patterns, such as insomnia or excessive sleepiness. However, individual reactions can vary.

Q: Is Fleboside considered a relatively new or well-established drug?

A: The active components of Fleboside, Troxerutin and Carbazochrome, have a history of clinical investigation and use in its therapeutic area spanning several decades. This clinical background indicates that the components are considered well-established.

Q: What is the typical duration of treatment with Fleboside?

A: The duration of treatment is defined by the form of the medicine being used. The solution for injection, used for acute management, is generally a short course limited to around 5 to 7 days, while the oral tablet form is intended for longer-term maintenance use.

Q: What does the research say about the effectiveness of Fleboside?

A: Clinical studies and reviews focusing on the components, particularly the flavonoid Troxerutin, suggest benefits in managing the symptoms of chronic venous insufficiency. Official documentation indicates that the fixed combination has demonstrated superiority over placebo in improving symptoms in specific acute conditions.

Q: Are there any official warnings about using Fleboside with Calcium supplements?

A: Regulatory documents indicate that co-administration with certain medications, including Calcium supplements, may potentially decrease the therapeutic action (efficacy) of the Troxerutin component. This is noted as a potential interaction that may affect how well the medicine works.

Q: Why do some people need to take Fleboside for a long time?

A: The medicine is indicated for managing the symptoms of chronic conditions, such as venous insufficiency, which often requires sustained therapeutic support. The oral form is specifically dosed for maintenance use to help sustain the functional effect on the microvasculature.

Q: Is it possible for a person to be allergic to Fleboside?

A: Yes, the medicine is formally contraindicated in individuals who have a known hypersensitivity or allergy to either of the active ingredients, Troxerutin or Carbazochrome, or to any of the other inactive components (excipients) in the product.

Q: Is Fleboside described as having a risk of dependence or addiction?

A: Official safety information reports that there are generally no known habit-forming tendencies or risk of dependence associated with the active components of Fleboside.

Q: Does Fleboside cause drowsiness?

A: Official safety data typically reports that Fleboside does not cause sleepiness or drowsiness. However, dizziness is listed as a common side effect of the medicine.

Q: What happens if I accidentally take too much Fleboside?

A: Official product information indicates that in the event of taking a dose greater than prescribed, patients are advised to seek guidance from a healthcare professional.

Q: Is there a generic version of Fleboside available?

A: The active ingredients, Troxerutin and Carbazochrome, are available in generic form or under different brand names globally. However, the availability of a direct generic equivalent for this specific fixed-dose combination product may vary depending on the country or region.

Q: Are there specific instructions for stopping the use of Fleboside?

A: The medicine should not be discontinued without the explicit instruction of a healthcare provider. Any decision regarding cessation of treatment typically requires professional guidance.

Q: Are there any specific lifestyle changes recommended when taking Fleboside?

A: Official patient information often includes general health advice. This typically involves maintaining a balanced diet, ensuring adequate rest and hydration, and avoiding smoking or excessive alcohol consumption, alongside taking the prescribed medicine.

How should Fleboside be stored and disposed of?

How to Store and Dispose of Fleboside

The storage and disposal requirements for Fleboside are strictly defined in official regulatory documents to ensure product stability and safety. The medicine must be stored at a temperature below 25 C or 30 C, depending on the specific national label, and must be protected from both light and moisture.

Required Storage Conditions

Requirement Instruction
Temperature Store below 25 C or 30 C.
Protection Keep in the original package, protected from light and moisture.
Child Safety Keep out of the sight and reach of children.

Disposal Instructions

Unused or expired Fleboside must be disposed of according to local pharmaceutical waste regulations. It is strictly prohibited to discard the medicine with household trash or to flush it into wastewater, which ensures environmental protection.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fleboside found in:

A-Z Index: